Co-Diagnostics, Inc. to Present its Rapid Response to New Coronavirus in Washington D.C. Conference
February 13 2020 - 6:30AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of diagnostic tests, announced today that it has been
invited to be a featured speaker to present its rapid response to
the new coronavirus (Covid-19) global health concern, as well as
its multiplex PCR solutions for mosquito-borne diseases, at the 3rd
International Conference on Zika Virus and Aedes Related
Infections. The conference will take place on February 13-16, 2020
in Washington D.C.
The Company will report how its proprietary design platform
allowed Co-Diagnostics scientists to work quickly in response to
the threat of the new strain of coronavirus. In addition to its
work on coronavirus, the Company will showcase its infectious
disease initiative, which incorporates its vector control solutions
that it began commercializing in 2019. Co-Diagnostics Vector Smart™
assays include multiplex polymerase chain reaction (PCR) tests for
Zika/dengue/chikungunya, and West Nile/St. Louis
encephalitis/eastern equine encephalitis, among others. The Company
also offers laboratory equipment and training packages, and has
been marketing and selling its products to mosquito abatement
districts across the country.
Co-Diagnostics Logix Smart™ diagnostics for Aedes mosquito-borne
diseases include a CE-marked multiplex PCR assay for
Zika/dengue/chikungunya. According to the World Health
Organization, the global incidence of dengue alone has grown
dramatically in recent decades. About half of the world's
population is now at risk, with an estimated 390 million infections
each year.
Brent Satterfield, Chief Science Officer (CSO) and founder of
Co-Diagnostics, remarked, “Our ability to respond quickly in the
face of an emergency is made possible thanks to the diligent work
of Co-Diagnostics researchers and scientists, and their ability to
apply our design platform to address global health concerns.
“However, in the time that the novel strain of coronavirus has
captured the world’s attention, thousands more have continued to
become infected, suffer, and even die from mosquito-borne illnesses
that are often unknown in the developed world until outbreaks
occur. Our catalog of highly-specific assays includes multiplex
solutions for both vector control as well as in vitro diagnostics
for human testing, and I am pleased to be able to present the
quality of our technology to the dedicated, multi-disciplinary
participants at this conference.”
The Company’s presentation is scheduled to take place on
Saturday, February 15th at 12:45 PM, and will be conducted jointly
by its CSO and Head of International Sales.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding the (i) use of
funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, and (viii) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200213005293/en/
Company Contact: Andrew Benson Head of Investor Relations
+1 801-438-1036 investors@codiagnostics.com Media Contact:
Jennifer Webb Coltrin & Associates, Inc +1.267.912.1173
jennifer_webb@coltrin.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024